Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexagliflozin in type 2 diabetes mellitus with moderate renal impairment
2016-002580-34Phase 3Completed
- Sponsor
- Theracos, Inc.
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Bexagliflozin with Placebo (2 arms). Primary endpoint: Change in HbA1c from baseline to week 24. Started Aug 2016; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2016-002580-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002580-34.